Resources from the same session
CDK4-6 inhibition in patients with metastatic HR positive / HER2 negative breast cancer: Benefit in endocrine resistant disease
Presenter: A. Marra, IT
Session: Session 2 - CDK4-6 inhibitors in advanced breast cancer
Resources:
Slides
Webcast